Allergic rhinitis,AR
Conditions
Interventions
Trials Group1:Tuoming Tiaoqiao prescription
Trials Group2:Oral Tuoming Tiaoqiao prescription combined with Centipeda minima Powder
Control group:Topical mometasone gluconate nasal spray
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medicine University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the above diagnostic criteria of traditional Chinese and western medicine; 2. Regardless of gender, aged between 18 and 60 years old, patients who can objectively and accurately express the efficacy of treatment; 3. The subjects informed consent and signed the informed consent form; 4. In the course of treatment in this study, no longer accept other treatments that may affect the results of observation.
Exclusion criteria
Exclusion criteria: 1. Those who do not meet the above inclusion criteria; 2. Pregnant or lactating women; patients with severe primary diseases such as cardio-cerebrovascular, liver, kidney and hematopoietic system, and patients with severe mental disorders; patients with allergic asthma. Patients with drug allergy to nasal sinusitis or rhinosinusitis; 3. Have received related treatment, and the patients who will affect the observation index after inclusion in the study; 4. The patients with poor compliance and failure to carry out treatment according to the regulations; 5. Within 2 months before treatment, the related treatment of nasal mucosal administration will be included in the patients who will affect the observation index after the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rhinitis symptom score criteria, TSSN; | — |
Secondary
| Measure | Time frame |
|---|---|
| Allergic rhinitis Quality of life scale, RQLQ;TCM syndrome score; | — |
Countries
China
Contacts
Public ContactZhu Bo
The First Affiliated Hospital of Zhejiang Chinese Medicine University
Outcome results
None listed